Literature DB >> 17510061

Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions.

Maher Al-Ayyoubi1, Bradford S Schwartz, Peter G W Gettins.   

Abstract

Maspin is a member of the serpin family with a reactive center loop that is incompatible with proteinase inhibition by the serpin conformational change mechanism. Despite this there are reports that maspin might regulate uPA-dependent processes in vivo. Using exogenous and endogenous fluorescence, we demonstrate here that maspin can bind uPA and tPA in both single-chain and double-chain forms, with K(d) values between 300 and 600 nM. Binding is at an exosite on maspin close to, but outside of, the reactive center loop and is therefore insensitive to mutation of Arg(340) within the reactive center loop. The binding site on tPA does not involve the proteinase active site, with the result that maspin can bind to S195A tPA that is already complexed to plasminogen activator inhibitor-1. The ability of maspin to bind these proteinases without involvement of the reactive center loop leaves the latter free to engage in additional, as yet unidentified, maspin-protein interactions that may serve to regulate the properties of the exosite-bound proteinase. This may help to reconcile apparently conflicting studies that demonstrate the importance of the reactive center loop in certain maspin functions, despite the inability of maspin to directly inhibit tPA or uPA catalytic activity in in vitro assays through engagement between its reactive center loop and the active site of the proteinase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510061     DOI: 10.1074/jbc.M702445200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Maspin increases extracellular plasminogen activator activity associated with corneal fibroblasts and myofibroblasts.

Authors:  Debra J Warejcka; Malathi Narayan; Sally S Twining
Journal:  Exp Eye Res       Date:  2011-07-27       Impact factor: 3.467

2.  Internalization by multiple endocytic pathways and lysosomal processing impact maspin-based therapeutics.

Authors:  Thomas M Bodenstine; Richard E B Seftor; Elisabeth A Seftor; Zhila Khalkhali-Ellis; Nicole A Samii; J Cesar Monarrez; Grace S Chandler; Philip A Pemberton; Mary J C Hendrix
Journal:  Mol Cancer Res       Date:  2014-09-25       Impact factor: 5.852

3.  Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion.

Authors:  Michael P Endsley; Yanqiu Hu; Yong Deng; Xiaolin He; Debra J Warejcka; Sally S Twining; Steven L Gonias; Ming Zhang
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

4.  G-helix of maspin mediates effects on cell migration and adhesion.

Authors:  Lorna Ravenhill; Laura Wagstaff; Dylan R Edwards; Vincent Ellis; Rosemary Bass
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

5.  Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.

Authors:  M Margarida Bernardo; Alexander Kaplun; Sijana H Dzinic; Xiaohua Li; Jonathan Irish; Adelina Mujagic; Benjamin Jakupovic; Jessica B Back; Eric Van Buren; Xiang Han; Ivory Dean; Yong Q Chen; Elisabeth Heath; Wael Sakr; Shijie Sheng
Journal:  Cancer Res       Date:  2015-07-24       Impact factor: 12.701

Review 6.  Exosite determinants of serpin specificity.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2009-04-28       Impact factor: 5.157

7.  Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate.

Authors:  Long-jiang Shao; Heidi Y Shi; Gustavo Ayala; David Rowley; Ming Zhang
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.

Authors:  Michel S Beausoleil; Erika B Schulze; David Goodale; Carl O Postenka; Alison L Allan
Journal:  BMC Cancer       Date:  2011-01-19       Impact factor: 4.430

9.  Maspin is not required for embryonic development or tumour suppression.

Authors:  Sonia S Y Teoh; Jessica Vieusseux; Monica Prakash; Susan Berkowicz; Jennii Luu; Catherina H Bird; Ruby H P Law; Carlos Rosado; John T Price; James C Whisstock; Phillip I Bird
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.